- Global Pharma News & Resources

Takara Bio enters into a license and supply agreement of RetroNectin® with BioNTech Cell & Gene Therapies GmbH

Kusatsu/Shiga, Japan — June 24, 2021Life Science Newswire – Takara Bio Inc. announces that it has entered into a License and Supply Agreement with BioNTech Cell & Gene Therapies GmbH (“BioNTech”), a BioNTech SE company (, Germany, under which Takara Bio grants BioNTech a commercial license to use applicable patents relating to RetroNectin®. Under this agreement, Takara Bio provides BioNTech with reliable supplies of RetroNectin®.

The patented technologies licensed to BioNTech are based on Takara Bio’s proprietary RetroNectin® method, which includes a technology enabling highly efficient gene transduction to cells by retrovirus/lentivirus vector and expansion of T-cells with high efficiency. With such advantages, RetroNectin® method is one of the mostly used standard protocols utilized for “Engineered T-cell Therapy”, which includes promising TCR and CAR gene therapies recently raising higher expectations.

Under the agreement signed with Takara Bio, BioNTech is allowed to use RetroNectin® for production of its cell & gene therapy products, therapies in which a patient’s T cells are genetically engineered to express a CAR for the treatment of multiple solid tumors.

Takara Bio is promoting supply of RetroNectin® to clinical development of Engineered T-cell Therapy actively pursued worldwide in recent years, and expects higher sales growth in the future.

About Takara Bio Inc.
Takara Bio Inc., a world leader in biotechnology research and development, offers a host of life science research solutions, from enzymes and GMP-grade reagents to contracted cell and gene therapy manufacturing services and is the developer of the RetroNectin reagent, a world standard in gene therapy protocols. Takara Bio is committed to preventing disease and improving the quality of life for all people through the use of biotechnology.

Editor Details

Last Updated: 24-Jun-2021